- Home
- GGG vs RPRX Comparison
GGG vs RPRX Comparison
Compare GGG & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGG
- RPRX
- Stock Information
- Founded
- GGG 1926
- RPRX 1996
- Country
- GGG United States
- RPRX United States
- Employees
- GGG N/A
- RPRX N/A
- Industry
- GGG Fluid Controls
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- GGG Industrials
- RPRX Health Care
- Exchange
- GGG Nasdaq
- RPRX Nasdaq
- Market Cap
- GGG 14.0B
- RPRX 15.6B
- IPO Year
- GGG N/A
- RPRX 2020
- Fundamental
- Price
- GGG $83.47
- RPRX $36.03
- Analyst Decision
- GGG Buy
- RPRX Strong Buy
- Analyst Count
- GGG 2
- RPRX 4
- Target Price
- GGG $94.00
- RPRX $44.50
- AVG Volume (30 Days)
- GGG 667.4K
- RPRX 5.2M
- Earning Date
- GGG 10-22-2025
- RPRX 11-05-2025
- Dividend Yield
- GGG 1.32%
- RPRX 2.44%
- EPS Growth
- GGG N/A
- RPRX 54.86
- EPS
- GGG 2.82
- RPRX 2.32
- Revenue
- GGG $2,167,974,000.00
- RPRX $2,305,243,000.00
- Revenue This Year
- GGG $7.32
- RPRX $35.14
- Revenue Next Year
- GGG $4.19
- RPRX $1.24
- P/E Ratio
- GGG $29.61
- RPRX $15.51
- Revenue Growth
- GGG 0.75
- RPRX 3.02
- 52 Week Low
- GGG $72.06
- RPRX $24.05
- 52 Week High
- GGG $92.86
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- GGG 41.44
- RPRX 51.05
- Support Level
- GGG $83.55
- RPRX $35.36
- Resistance Level
- GGG $85.26
- RPRX $36.67
- Average True Range (ATR)
- GGG 1.18
- RPRX 0.74
- MACD
- GGG -0.10
- RPRX 0.08
- Stochastic Oscillator
- GGG 1.89
- RPRX 68.36
About GGG Graco Inc.
Graco manufactures equipment used for managing fluids, coatings, and adhesives, specializing in difficult-to-handle materials. Graco's business is organized into three segments: industrial, process, and contractor. The Minnesota-based firm serves a wide range of end markets, including industrial, automotive, and construction, and its broad array of products include pumps, valves, meters, sprayers, and equipment used to apply coatings, sealants, and adhesives. The firm generated roughly $2.1 billion in sales in 2024.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.